Buyback of Class B shares in Essity during week 2, 2026

Essity repurchased 57,798 Class B shares on Nasdaq Stockholm between January 5–9, 2026 at a weekly weighted average price of SEK 261.14, totaling SEK 15.09m, as part of its SEK 3bn buyback program announced April 23, 2025. The program—implemented in line with MAR and the Safe Harbour Regulation—has accumulated 9,294,830 shares (avg SEK 258.48) valued at SEK 2.403bn to date; post-purchases Essity holds 10,077,330 Class B treasury shares out of 693,054,489 total shares. The repurchases are financed from cash flow after the ordinary dividend and signal ongoing capital return policy that should modestly support EPS and investor sentiment over time.

Analysis

Market structure: Essity’s SEK 3bn program (~1.66% of an estimated SEK 181bn market cap) has converted ~9.29m shares so far (≈1.34% of shares outstanding) into treasury stock, creating modest EPS accretion (~1.3% if fully executed) and reducing free float by ~1.45%. Short-term liquidity impact is small—weekly buys of ~57.8k shares are immaterial versus daily ADV for a ~SEK180bn cap stock—but persistent buybacks signal management preference for capital returns over immediate reinvestment.

Competitive dynamics & supply/demand: The program does not alter product-market share in hygiene/health markets, but it reallocates cash from reinvestment to shareholder returns, implying management sees limited high-return organic/M&A opportunities in the next 12–24 months. For investors this shifts the company’s implied valuation multiple higher via buyback-driven EPS rather than operational leverage.

Cross-asset/Risk: Expect muted equity volatility compression in ESSITY B (SE: ESSITY B) and marginal improvement in credit optics; FX moves (SEK/EUR) remain a larger earnings risk given ~EUR13bn sales. Tail risks include regulatory changes to EU buyback rules, a sudden slowdown in European consumer demand that reverses buyback rationale, or an FX shock; these are low probability but high impact over 3–12 months.

Catalysts & timing: Key near-term catalysts are remaining buyback deployment (~SEK600m capacity), Q1 earnings / AGM timing, and Swedish/Euro consumer indicators over next 1–3 quarters. If management accelerates purchases (use >50% remaining within 30 days) or signals further programs at AGM, expect a discrete re-rating; absence of further action shifts focus back to organic growth metrics.

Key Decisions for Investors

• Establish a 2–3% long position in ESSITY B (SE: ESSITY B) within the next 4 weeks to capture buyback-driven support and expected ~1–3% EPS uplift; target 3–6 month price target 280 SEK (~7–10% upside from ~261 SEK), stop-loss at 239 SEK (-8%).
• Buy a 3-month call spread on ESSITY B: buy 260 SEK call / sell 300 SEK call to lever limited-cost upside if buyback execution accelerates or AGM signals additional returns; size to equal ~1–2% portfolio delta exposure.
• Implement a relative-value pair: long ESSITY B (2% weight) vs short Kimberly-Clark (KMB, 1–1.2% weight) for 3–6 months to isolate buyback/return-on-capital rerating vs US peer; rebalance if spread moves >4% intramonth.
• If remaining buyback capacity is deployed >50% within 30 days or management announces another program at AGM, increase ESSITY B exposure to 4% and consider selling 30–60 day covered calls at ~5–7% OTM to harvest premium; if buyback halts and organic sales growth <0% YoY on next report, reduce exposure to <1%.